New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
07:20 EDTNAVBNavidea price target raised to $5 from $3 at JMP Securities
JMP Securities increased its price target on Navidea after the company reported higher than expected Q2 Lymphoseek sales and operating income. The firm thinks the company has a number of significant growth drivers and keeps an Outperform rating on the shares.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
07:41 EDTNAVBNavidea reports data on Lymphoseek vs. Sulfur Colloid in breast cancer
Navidea Biopharmaceuticals announced that an analysis comparing sentinel lymph node biopsy procedures using Lymphoseek injection + vital blue dye to filtered sulfur colloid + VBD in breast cancer patients was published in the Annals of Surgical Oncology. Results demonstrated the following: Lymphoseek patients had significantly fewer SLNs removed per procedure; Proportionally fewer nodes were necessary to detect cancer spread; and Nodes removed using Lymphoseek held greater predictive value for diagnosing spread of breast cancer to lymph nodes. The study was published in the January print issue of the journal, Annals of Surgical Oncology.
January 21, 2015
07:34 EDTNAVBNavidea's Macrophage Therapeutics unit announces plan for $2.5M financing
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use